INTRODUCTION

Position statements from the American Diabetes
Association and the European Association for the Study of Diabetes recommend an individual target of hemoglobin A 1c (HbA 1c ) [1] [2] [3] . The targets and the management of glycemia should be individualized and must be an integrated part of overall care for each particular patient [1, 3, 4] .
For patients with type 2 diabetes mellitus, clinical guidelines generally propose a step-wise progression of pharmacotherapy, with basal insulin as the next step when lifestyle changes and initial oral therapies have failed [1, 5] .
Various consecutive insulin regimens have been suggested, although with conflicting results regarding the use of basal versus prandial insulin [6, 7] and with little consensus regarding the best options for intensification [2] [3] [4] [5] 8] . The UK Prospective Diabetes Study (UKPDS) group reported that an initial decrease in HbA 1c was seen when patients started insulin, but there was a continual increase when followed long-term [9] . This is in contrast to the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, which showed that in early diabetes basal insulin only could be a long-term option [10] . Therefore, it is unclear how alternative insulin regimens perform under real-world conditions in regard to glycemic control.
The
INSulin TItration-GAining an understanding of the burden of Type 2 diabetes in Europe (INSTIGATE) observational study was designed to examine patients with type 2 diabetes who initiated insulin as part of their usual care [11] . Patients were initially recruited in France, Germany, Greece, Spain, and the UK, and results during the first 6 months have been reported [12] . Further follow-up continued in Germany, Greece, and Spain, and the present paper describes the changing clinical outcomes during the 24-month follow-up period.
PATIENTS AND METHODS
Patient Population and Study Design
Patients were recruited at primary and secondary care centres that routinely treated a large number of patients with type 2 diabetes, according to normal country-specific treatment practices for insulin initiation. Investigators were diabetologists, endocrinologists, and primary care physicians who were either directly responsible for initiating insulin therapy or were actively involved in further routine management of patients who had initiated insulin therapy. The study was noninterventional and, therefore, all treatment decisions were made by the physicians in consultation with the patients as part of usual care. For each country, local requirements for ethical review, informed consent, and other regulatory approvals for an observational study were met. Patient characteristics, therapy prior to insulin initiation, and differences between participating countries were described previously [11] . Patients had contact with their physicians within the normal course of therapy, and information was collected at baseline and approximately 3, 6, 12, 18, and 24 months after insulin initiation. For each patient throughout the study, insulin regimens and use of oral antidiabetic drugs (OADs) were recorded. HbA 1c and fasting blood glucose concentrations were measured at local laboratories using standard methods. Self-reported episodes of hypoglycemia were recorded retrospectively at each visit.
Statistical Analysis
Demographic characteristics, treatment status, and HbA 1c concentrations were assessed using descriptive summary statistics, with mean, SD, median, minimum, maximum, and quartiles calculated for continuous variables. Depending on skewing of the data, either mean and SD or median and quartiles were used for description. For categorical variables, absolute number of patients and percentages based on total number of patients per country and overall were calculated.
RESULTS
A total of 564 patients, out of 726 taking part in the initial 6-month part of the INSTIGATE study, were followed for up to 24 months in In Greece, no OAD use was reported by a similar proportion of patients at baseline (57.0%), but this decreased to 47.6% at 24 months, with a concomitant increase in the proportion taking one OAD from 30.4% at baseline to 41.0% at 24 months. The respective percentages for no OAD use for Spain were 40.1% at baseline and 27.0% at 24 months, with increases in the proportion taking one (baseline 40.1% to 24 months 48.7%) and two OADs (baseline 19.2% to 24 months 23.7%). OAD use included a sulfonylurea for 18.6% and 18.5% of patients in Greece at baseline and 24 months, 23.8% and 27.6%, respectively, in Spain, but only 5.2% and 3.4% in Germany.
Overall mean (SD) HbA 1c ( Fig. 1 At least one episode of hypoglycemia (Fig. 3) was reported by 5.0% of patients overall at baseline for the prior 3 months; assessments at each 6-monthly interval during the study indicated an increase to 24.5% at 6 months, and 15.3%, 16.6%, and 15.5% at the following visits (12, 18, and 24 months, respectively). The hypoglycemia incidence at 24 months was higher in Greece (23.3%) than Germany (10.1%) or Spain (7.9%). Throughout the study, seven patients reported hypoglycemia requiring hospitalization and confirmed by glucose readings, which included two prior to insulin initiation.
DISCUSSION
The present report of the INSTIGATE observational study assessed data from up to 24 months of follow-up for patients who initiated insulin in Germany, Greece, and Spain. Most guidelines/position statements recommend the initial use of basal insulin, with subsequent addition of prandial insulin when HbA 1c levels remain elevated [1] [2] [3] [4] [5] . In the present study, a majority of patients in Germany started on prandial insulin only, whereas most patients in Greece and Spain started on basal insulin only or premixed formulations. The difference in initial treatment patterns may reflect the fact that all of the investigators in Germany were specialist Table 2 Insulin regimens used at insulin initiation and 12 and 24 month after insulin initiation diabetologists [11] and may have adopted a different approach, based on different national guidelines [13] . Overall, changes in insulin regimens over the 24-month study were small, and 76% of patients did not change their insulin regimen from that initiated. In Germany, mean HbA 1c concentration was maintained below 7% from 6 months onwards. This could be due to the predominant use of multiple injections in Germany, starting with a prandial approach and intensification to basal/ bolus insulin, with increasing overall insulin dosage at 12 and 24 months. The maintenance of HbA 1c below 7% was consistent with the previously reported German study using a basal/ bolus regimen [14] . In Greece, a slow decline in mean HbA 1c was seen, almost reaching target levels at 24 months. An increase in use of a basal/bolus regimen at 12 and 24 months and a clinically relevant increase in insulin dosage could be seen, as well as an increase in the proportion of patients using concomitant OADs. However, 21 patients in Greece stopped using insulin altogether. In Spain, the lowest mean HbA 1c was achieved at 6 months with a rise to above 7.5% after 24 months. This outcome might be expected given the progressive pathophysiology of type 2 diabetes and the fact that there was little change in treatment regimens and insulin dosage in Spain, with the majority of patients remaining on basal insulin only. The authors would suggest that the greater improvement in glycemic control seen in Germany is most likely due to the insulin intensification, with more complex regimens and higher insulin dosage. Limitations of this interpretation were that the patient cohorts were not totally comparable between countries (e.g., the German cohort was younger and had a shorter duration of diabetes), the study was only observational and, therefore, no randomization or standardization of the treatment took place.
In addition, the authors observed only a limited number of patients and not all were willing to continue for 24 month, which may have caused a selection bias. reductions were significantly greater with biphasic and prandial insulin than with basal insulin alone [16] .
Consistent with the 6-month INSTIGATE results [12] , the rate of hypoglycemia was lower in Germany at 12, 18, and 24 months, despite the more intensive regimens and lower HbA 1c , compared with Greece where basal and premixed regimens were more widely used. This was in contrast to studies of patients treated with prandial insulin who had improved postprandial glucose and HbA 1c , but higher rates of hypoglycemia compared with patients treated with basal insulin alone [6, 17] . In a study by higher with rapid-acting prandial insulin than with basal insulin was shown [7, 18] . However, it has been suggested that the use of sulfonylureas in the prandial insulin group of APOLLO might have contributed to the higher rate of hypoglycemia [19] . While only 5% of patients in Germany reported concomitant sulfonylureas in the present study, the proportion in Greece was over 18%, which may relate to the higher incidence of hypoglycemia in Greece. However, in Spain approximately 25% reported concomitant sulfonylurea use, but the percentage reporting hypoglycemic episodes were generally lowest.
This might reflect the smaller HbA 1c reduction, the lowest insulin dosages, and the highest percentage of patients who stopped insulin use.
CONCLUSION
The majority of patients did not change insulin regimen from that initiated, indicating that guidelines of adaptation to individual patient needs are not sufficiently adhered to. Therapeutic algorithms suggest that basal insulin should be followed by a combination of basal with preprandial insulin to control postprandial glucose fluctuations [20] . 
